BSV Ventures
VC Fund
Vilnius, Lithuania
BSV Ventures is a venture capital business that only invests in early-stage deep technology and life science solutions.
- Total investments:
- 31
- Last investment:
- Lead investor:
- 42%
- Fund size:
- $18M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries BSV Ventures invests in
Stages BSV Ventures invests in
Countries BSV Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Round size
- Seed
- $207k–$2.3M
- Grant
- $64k–$134k
- Pre-Seed
- $328k–$1.4M
Investment Focus
Industry
- Software 4 (13%)
- Biotechnology 3 (10%)
- Manufacturing 3 (10%)
- Medical 2 (6%)
- Aerospace 2 (6%)
Stage
- Pre-Seed 14 (45%)
- Seed 8 (26%)
- Grant 2 (6%)
- Venture - Series Unknown 2 (6%)
- Series A 1 (3%)
Country
- Lithuania 8 (26%)
- Estonia 6 (19%)
- Finland 3 (10%)
- Spain 1 (3%)
- Sweden 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Andrius Milinavičius
General Partner
|
General Partner | Total investments: 3 | Find email | |
Dominykas Milasius
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
Erik Bhullar
General Partner
|
General Partner | Total investments: 2 | Find email | |
Sandra Golbreich
General Partner
|
General Partner | Total investments: 9 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Intu Diagnostics
|
Intu Diagnostics develops rapid and instrument-free solutions for infectious disease diagnostics, aiming for affordability and global accessibility. The company is committed to implementing a sustainable and socially responsible business model to contribute to better global health through its technology. The product portfolio includes solutionslike PCR-TO-GO, designed to bring doctor's office-level diagnostics to the patient's door. | $1.3M / Seed / Jun 25, 2026 | |
Emulsi Biotech
|
Emulsi Biotech is a biotechnology company that develops lipid technology to deliver biologic drugs orally. | $743K / Pre-Seed / Jun 16, 2026 | |
Granarium Technologies
|
Granarium Technologies is a Finnish deep-tech energy that creates renewable supercapacitors using only nanocellulose, biocarbon, and water, eliminating the need for mining entirely. | $1.2M / Pre-Seed / Jun 09, 2026 | |
Axiology
|
Axiology DLT offers an innovative infrastructure that simplifies the issuance, trading, and management of digital fixed-income instruments. We aim to reduce dependency on intermediaries, making capital raising processes faster and more cost-effective. Committed to collaboration, we see our role as part of a broader market ecosystem where everyonehas their place. Our infrastructure is designed to support sustainable growth, welcome partners, and drive collective progress. | $5.9M / Seed / Feb 04, 2026 | |
Halide Energy
|
Halide Energy solves the global needs for long-duration energy storage and grid resiliency through patented copper-redox flow batteries. | Venture - Series Unknown / Dec 24, 2025 | |
Repsense
|
Repsense is a data company that mimics user journeys and predicts reactions to content found in search results pages. any of the clients can use the Repsense Index to quickly assess their reputation and compare it to competitors across different geographies and user intents. | $2.3M / Seed / Dec 16, 2025 | |
Reveni
|
Reveni is an instant refund platform for e-commerce that prevents fraud in returns and delivers instant refunds to customers. | $8.8M / Series A / Sep 30, 2025 | |
C2Grid
|
C2Grid delivers AI-powered 3D situational awareness by transforming video into interactive, multi-layered intelligence. Its technology enhances tactical and operational visibility, accelerates decision-making, and improves mission outcomes. Designed for both military and civilian use, C2Grid’s solutions save time, boost efficiency, and ultimatelyprotect lives. | $353.7K / Pre-Seed / Sep 18, 2025 | |
|
Psylink
|
Psylink is a biotechnology company offering a novel solution to psychedelic drug development | $579.3K / Pre-Seed / Jul 29, 2025 | |
BrachyDOSE
|
BrachyDOSE is a cancer treatment quality control tool to help oncologists to reach best possible treatment results. For the oncologist the main problem performing radiotherapy procedure is lack of accurate and measurements based proof if tumor got the appropriate radiation dose, if healthy organs were damaged or stayed safe. The uncertainty leadsto radiation burning and secondary illnesses. Solution is suited specially for high dose rate brachytherapy procedure. We suggest the systems made of tool for radiation dose measurement (dosimeter) and its reader. Unlike other solutions in the market, which is dose simulation apps, our system shows the accurate science based data, is easy to use and it is highly compatible with standards devices. Our team is made of materials engineer, applied physicist, medical device engineer and a few medical doctors working in oncology field. We are focused on radiation sensitive materials research and device engineering +7 years. We have +10 years of experience in project leadership and scientific research. Team members has experience in development of successful projects with Lithuanian Health Science University Kaunas Clinics, National Cancer Institute (Lithuania). | $648.3K / Seed / Jul 10, 2025 | |
| See all 31 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does BSV Ventures invest in?
BSV Ventures invests primarily in Software, Biotechnology and Manufacturing startups, most often at Pre-Seed and Seed stage. Most of the 31 investments tracked by Shizune back companies in Lithuania. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is BSV Ventures's check size?
BSV Ventures typically joins rounds of $207k–$2.3M at Seed, $64k–$134k at Grant and $328k–$1.4M at Pre-Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds BSV Ventures participates in.
How do I contact BSV Ventures?
Public channels for BSV Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at BSV Ventures?
The team at BSV Ventures includes Andrius Milinavičius (General Partner), Dominykas Milasius (Venture Partner) and Erik Bhullar (General Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
